💊
Loqtorzi
toripalimab
Nasofaryngeal cancer;Esofageal skivepitelcancer
✅ Auktoriserad
✅
Inga aktiva aviseringar
Denna medicin har inga pågående brister, säkerhetsbrev eller återkallelser.
Vad det används till
Loqtorzi, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. Loqtorzi, in combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
⚠️ Patientsäkerhet
No
Officiell EMA-sida
https://www.ema.europa.eu/en/medicines/human/EPAR/loqtorzi